Aug. 12 Quick Takes: another hold for Aprea’s eprenetapopt
Plus Vyne, AlzeCure and Jazz
FDA placed a clinical hold on eprenetapopt from Aprea Therapeutics Inc. (NASDAQ:APRE) in combination with acalabrutinib or venetoclax and rituximab to treat lymphoid malignancies. The announcement follows a partial hold FDA placed on the reactivator of mutant and inactivated TP53 last week in combination with azacitidine in its myelogenous malignancy programs based on concerns over safety and efficacy data in a Phase III trial to treat myelodysplastic syndrome. Aprea shares were off $0.06 to $4.04.
Vyne Therapeutics Inc. (NASDAQ:VYNE) lost 31% to $1.99 Thursday after unveiling plans to sell or out-license its topical minocycline franchise as it changes gears to focus on immunological and inflammatory disease. Separately, under a deal with University of Dundee spinout In4Derm Ltd., Vyne exercised its option to develop topical BET inhibitors for rare dermatological indications and expects to exercise an exclusive option to develop oral BET inhibitors following selection of a lead candidate. ...